IPA to host 8th edition of Global Pharmaceutical Quality Summit

Theme: ‘Patient Centricity – New Paradigm of Manufacturing and Quality

Two-day flagship event from 22-23 June in Mumbai; Top industry leaders expected to attend

Mumbai, 13th June 2023: The Indian Pharmaceutical Alliance (IPA) is all set to host the eighth edition of the Global Pharmaceutical Quality Summit (GPQS) from 22nd to 23rd June in Mumbai. The theme for this year’s annual flagship event is ‘Patient Centricity: New Paradigm of Manufacturing and Quality’. The Summit aims to bring diverse stakeholders together, including global regulators, technical experts, and industry stakeholders on a common platform to discuss the key imperatives of operations and build on the Indian pharma industry’s quality and manufacturing agenda going forward.

Samir Mehta, President, IPA and Chairman of Torrent Indian Pharmaceuticals Ltd, will address during the inaugural session, which will be attended by stakeholders from government, industry and global experts. This will be followed by the release of IPA’s Best Practices document.

The Summit will witness speakers from key regulators such as DCGI, USFDA, MHRA, EDQM, and others as part of the conference, who will share their perspectives on observations on inspection, GMPs, global regulatory view, resilience in end-to-end operations, and increased focus on quality compliance and excellence. Furthermore, there are key technical sessions such as continuous manufacturing, nitrosamines impurities, digital analytics, and automation among others.

Mr Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, said, “During the COVID-19 pandemic, the Indian pharmaceutical industry ensured an uninterrupted supply of quality-assured medicines to patients around the globe. India is now recognized as ‘The Pharmacy of the World’. Quality is a fundamental tenet of the pharmaceutical sector. IPA is committed to making India the global quality benchmark. The industry’s landscape is evolving at an unprecedented pace and hence we need to continuously invest in upgrading quality standards. 8th GPQS summit is an effort by IPA to bring domain experts, global regulators, and industry at one platform to drive discussions on big priorities which aim to define the next decade for pharmaceutical operations and manufacturing”.

The knowledge partner for the summit is McKinsey & Company. The summit will conclude with a special panel discussion comprising CEOs of leading pharma companies such as Cipla, Dr Reddy’s, Lupin, Sun Pharma, and Zydus, to deliberate on Vision 2047 for the Indian pharmaceutical industry and the way forward.

About IPA:
Indian Pharmaceutical Alliance represents 24 research-based national pharmaceutical companies. Collectively, IPA companies account for over 85 percent of the private sector investment in pharmaceutical research and development. They contribute more than 80 per cent of the country’s exports of drugs and pharmaceuticals and service over 60 per cent of the domestic market.
For more information, visit https://www.ipa-india.org/

For media queries, please contact:

Dolly Mahayan: 8585998496
dollym@avianwe.com

Nisha Boruah: 7836911132
nishab@avianwe.com